Sector News

Brexit ambition is ‘fine’ but execution is key, says Brexit Health Alliance

July 16, 2018
Life sciences

The co-chair of the Brexit Health Alliance, Niall Dickson, has welcomed the ambition of the government’s Brexit white paper but warned that execution will be key.

“The ambition is fine – but we await the execution,” said Dickson, who is Chief Executive of the NHS Confederation. “Patients in the UK and Europe need to know that they will get their drugs on time, that vital medical research will not be disrupted and that they will continue to get the healthcare they need while on holiday or travelling for work.”

“These are not theoretical possibilities, they are real risks which can and must be resolved in the negotiations. We have consistently called for assurances on all these matters and we welcome the government’s clear ambition to deal with them.

He added: “We also welcome the commitment to maintaining the highest standards of health protection after the UK leaves the EU. Maximum co-operation to control infectious diseases and other public health threats is a ‘no brainer’. But these are complex and wide-ranging negotiations and there is always a danger that health issues are not kept to the fore.

“We should be under no illusions of the consequences for patients if we fail to plan properly and do not reach a good agreement. That could result in a significant threat to the health of both UK and EU citizens.

“Planning is underway at the centre of government, but it will be important for the sake of patients that NHS hospitals, clinics and community services are all prepared for every possible scenario.”

The Brexit Health Alliance brings together the NHS, medical research, industry, patients and public health organisations, with the aim to safeguard the interests of patients and the healthcare and research they rely on during the Brexit negotiations.

The Alliance is working to ensure that issues such as healthcare research, access to technologies and treatment of patients are given the prominence and attention they deserve in the Brexit negotiations, and argues that it is in both Europe and the UK’s interests to maintain co-operation in research and in handling public health issues. It has also called on the UK government to make sure there is a commitment to medical research and providing alternative funding, and that UK citizens’ right to receive healthcare in EU countries is preserved.

By: George Underwood
Source: Pharma Times

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.